Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Pliant Therapeutics, Inc.
- Where
- Ann Arbor, Atlanta, Boston, Chicago, Durham, Houston, Indianapolis, Lakewood Rch, Miami, Nashville, New Haven, Newport News, Novi, Pasadena, Philadelphia, Redwood City, Richmond, Sacramento, San Francisco, and Seattle, United StatesSee the 21 sitesAlso in 8 other countries, 39 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 121 people enrolled
- Started
- 27 Jul 2020
- Ended
- 18 Mar 2024
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PLN-74809
- Placebo
- Record updated
- 23 January 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Established clinical diagnosis of large duct PSC based on an abnormal cholangiography as assessed by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), and/or percutaneous transhepatic cholangiopancreatography (PTC) in the context of cholestatic liver chemistry
- Suspected liver fibrosis, as defined by liver stiffness measurement (LSM), assessed by ultrasound-based transient elastography (TE, FibroScan®) OR Enhanced Liver Fibrosis (ELF) Score OR Historical liver biopsy showing fibrosis without cirrhosis (by any scoring system) OR Magnetic resonance elastography (MRE)
- Serum ALP concentration within normal limits or > 1 times the upper limit of normal (ULN)
- Participants receiving treatment for IBD are allowed, if on a stable dose from screening and expected to remain stable for the duration of the study
- Serum AST and ALT concentration ≤ 5 times the upper limit of normal
- If receiving treatment with UDCA, therapy is at a dose of < 25 mg/kg/day, has been stable for at least 3 months before screening
Who cannot take part
- Other causes of liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
- Known or suspected overlapping clinical and histologic diagnosis of autoimmune hepatitis
- Presence of liver cirrhosis as assessed by liver histology, ultrasound-based liver stiffness measurement, ELF score, MRE, and/or signs and symptoms of hepatic decompensation (including but not limited to, jaundice, ascites, variceal hemorrhage, and/or hepatic encephalopathy
- Serum ALP concentration > 10 times the upper limit of normal
- Small duct PSC with no evidence of large duct involvement (evidence of PSC on historical liver histology, with normal bile ducts on cholangiography)
Where in United States
Also in 8 other countries, 39 sites
- University of MichiganAnn Arbor, United States
- Piedmont Atlanta HospitalAtlanta, United States
- Massachusetts General Hospital Gastroenterology Liver CenterBoston, United States
- University of Chicago Medical CenterChicago, United States
- Duke University Medical CenterDurham, United States
- Baylor College of Medicine - Advanced Liver TherapiesHouston, United States
- Indiana University Health University HospitalIndianapolis, United States
- Florida Research InstituteLakewood Rch, United States
- Schiff Center of Liver Diseases/University of MiamiMiami, United States
- Vanderbilt Digestive Disease CenterNashville, United States
- Yale School of MedicineNew Haven, United States
- Bon Secours Liver Institute of Hampton RoadsNewport News, United States
- Henry Ford Health SystemNovi, United States
- California Liver Research InstitutePasadena, United States
- Perelman Center for Advanced MedicinePhiladelphia, United States
- Stanford University School of MedicineRedwood City, United States
- VCU Health Clinical Research Services UnitRichmond, United States
- University of California, Davis Medical CenterSacramento, United States
- California Pacific Medical Center Research InstituteSan Francisco, United States
- University of California San FranciscoSan Francisco, United States
- Liver Institute NorthwestSeattle, United States
About the trial
What the trial wants to find out
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
The 5 groups in the trial
- PlaceboPlacebo, for comparison
Placebo (Part 1, 2, and 3)
- PLN-74809 Dose Level 1Treatment being tested
Part 1, Cohort 1 Dose: 40 mg, up to 12 weeks
Treatment: PLN-74809
- PLN-74809 Dose Level 2Treatment being tested
Part 2, Cohort 2 Dose: 80 mg, up to 12 weeks; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
Treatment: PLN-74809
- PLN-74809 Dose Level 3Treatment being tested
Part 2, Cohort 3 Dose: 160 mg, up to 12 weeks; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 1
Treatment: PLN-74809
- PLN-74809 Dose Level 4Treatment being tested
Part 3, Cohort 4 Dose: 320 mg, for at least 24 weeks and up to 48 weeks; PLN-74809 Dose Level 4 following PLN-74809 Dose Levels 2 and 3
Treatment: PLN-74809
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
- Publications
- Record updated
- 23 January 2026